Mortality risk in atrial fibrillation: the role of aspirin, vitamin K and non-vitamin K antagonists

Emilie Gieling, Frank de Vries, Rachael Williams, Hein A W van Onzenoort, Anthonius de Boer, Vincent Ten Cate, Cornelis Kramers, Andrea Burden

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1536-1544
Number of pages9
JournalInternational Journal of Clinical Pharmacy
Volume41
Issue number6
Early online date8 Oct 2019
DOIs
Publication statusPublished - Dec 2019

Keywords

  • APIXABAN
  • Anticoagulants
  • Atrial fibrillation
  • Coumarins
  • DABIGATRAN
  • EFFICACY
  • METAANALYSIS
  • Mortality
  • NOACs
  • Non vitamin K oral anticoagulants
  • ORAL ANTICOAGULANTS
  • POPULATION
  • RIVAROXABAN
  • SAFETY
  • STROKE
  • Vitamin K antagonists
  • WARFARIN

Cite this

Gieling, E., de Vries, F., Williams, R., van Onzenoort, H. A. W., de Boer, A., Ten Cate, V., Kramers, C., & Burden, A. (2019). Mortality risk in atrial fibrillation: the role of aspirin, vitamin K and non-vitamin K antagonists. International Journal of Clinical Pharmacy, 41(6), 1536-1544. https://doi.org/10.1007/s11096-019-00916-1